[Asuka Pharmaceutical] Introduction of Countermeasures Against Large-Scale Purchase Attempts ｜ May 2026

Implementation of Countermeasures for the Shareholders' Meeting

Asuka Pharmaceutical is scheduled to hold a shareholders' meeting on June 24, 2026, where it plans to submit a proposal to authorize the implementation of countermeasures in anticipation of purchase attempts by Dalton and others. This framework allows the company to activate countermeasures without shareholder approval if the purchase activities do not adhere to the established procedural guidelines. The Board of Directors respects the recommendations of the Independent Committee and is preparing responses to maximize corporate value and shareholder interests.

Future Outlook and Impact on Shareholders

As the likelihood of Dalton and others executing large-scale purchase attempts increases, Asuka Pharmaceutical intends to seek shareholder approval at the upcoming general meeting to activate countermeasures aimed at preventing damage to long-term corporate value. If purchase activities occur, the company will protect minority shareholders’ interests and ensure management stability while addressing conflicts of interest and hostile takeover risks. These actions aim to safeguard shareholder interests and promote sustainable corporate growth.